
|Articles|May 31, 2012
Bevacizumab improves BCVA and central macular thickness in CSME patients
Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement




















